Teste de drogas do metabolismo em modelo transgênico de Drosophila melanogaster para doença de Alzheimer

• Ano de defesa: 2019
• Autor(a) principal: Morandi Filho, Romualdo
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Uberlândia; Brasil; Programa de Pós-graduação em Genética e Bioquímica
• Palavras-chave em Português: Genética; Genetics; Doença de Alzheimer; Alzheimer's disease; Metabolismo da glicose; Glucose metabolism; Drosophila melanogaster; CNPQ::CIENCIAS BIOLOGICAS::GENETICA; Alzheimer, Doença de; Glicose; Metabolismo
• Link de acesso: https://repositorio.ufu.br/handle/123456789/29734; http://dx.doi.org/10.14393/ufu.te.2019.2193

Alzheimer's disease is a progressive neurodegenerative disease, and the most common form of dementia, and even after more than 100 years of its discovery, the mechanisms of onset and progression of the disease have not yet been fully elucidated. Studies have shown a strong relationship between Alzheimer's disease and glucose metabolism, and that the use of some metabolic drugs may reduce the progression of the disease, but the way these drugs lead to this beneficial effect is still a matter of discussion. This work aimed to evaluate a transgenic lineage of D. melanogaster as a model for the study of these drugs, as well as to propose possible routes of action for the effect of these drugs. We demonstrated that not only did glimepiride, metformin and simvastatin have beneficial effects on disease progression, demonstrating that this is a good model for the study of these drugs, as we have shown that all interact in the Akt / mTOR and Hsp70 pathway. We also discovered changes in the transcription rate of mitochondrial RNA and new miRNAs and lncRNAs with targets related to phenotype similar to Alzheimer's disease of this model.